Treatments For Skeletal Muscle Abnormalities In Heart Failure Sodium Glucose Transporter 2 And Ketone Bodies

Heart failure doesn't just affect the heart - it also causes significant problems in skeletal muscles throughout the body. These muscle abnormalities, particularly issues with how muscles produce and use energy, are a major reason why people with heart failure struggle with exercise and daily activities. The root problem appears to be mitochondrial dysfunction, where the cellular "powerhouses" in muscle cells can't efficiently convert nutrients into usable energy.

This research review explores whether SGLT2 inhibitors - medications originally developed for diabetes that help the kidneys remove excess glucose - might offer a new treatment approach for these muscle problems. These drugs have already shown surprising benefits for heart failure patients in large clinical trials, reducing cardiovascular events even beyond their blood sugar effects. The researchers believe this may be because SGLT2 inhibitors increase ketone bodies in the blood, which could serve as an alternative, more efficient fuel source for damaged muscle mitochondria.

The theory is that by providing ketones as fuel and improving fatty acid metabolism while reducing the muscles' dependence on glucose, these medications could restore more normal energy production in skeletal muscle. This could potentially improve exercise capacity and reduce the fatigue that significantly impacts quality of life for heart failure patients.

While this research is still in the investigational phase, it represents an exciting possibility for addressing the muscle-related symptoms of heart failure that have previously had no specific treatments. For patients and clinicians, this highlights how metabolic interventions might address complications beyond their primary targets, offering hope for more comprehensive treatment approaches.